Skip to main content
Premium Trial:

Request an Annual Quote

DV Biologics, System Biosciences Ink Stem Cell Partnership

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DV Biologics and System Biosciences this week announced a partnership to develop human-derived, disease-specific induced pluripotent stem cell lines.

Under the terms of the deal, System Biosciences will convert many of DV Biologics' disease-specific cell types into iPSCs, using its proprietary products for reprogramming and iPSC generation, the two firms said in a statement.

System Biosciences will exclusively market several iPSCs developed under the agreement. No financial terms of the deal were disclosed.

DV Biologics is headquartered in Costa Mesa, Calif., and is a supplier of human primary cells and cell-derived products. System Biosciences is based in Mountain View, Calif., and develops and commercializes technologies for genomic- and proteomic-based investigations.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.